TG Therapeutics Inc (TGTX) saw its stock rise by 8.47% as it crossed above the 5-day SMA, reflecting strong investor interest.
The company announced a projected global revenue of $616 million for 2025, surpassing analyst estimates of $606 million, which indicates robust market performance and growth potential. Additionally, the U.S. net product revenue for BRIUMVI is expected to reach approximately $182 million in Q4 2025, showcasing the product's increasing acceptance. Despite a broader market decline, TGTX's optimistic revenue outlook has led to a significant stock rally, demonstrating investor confidence.
This positive financial projection positions TG Therapeutics favorably in the biopharmaceutical sector, potentially attracting more investment as it prepares for future milestones, including pivotal data from the ENHANCE trial by mid-2026.
Wall Street analysts forecast TGTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TGTX is 43.50 USD with a low forecast of 15.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast TGTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TGTX is 43.50 USD with a low forecast of 15.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
1 Sell
Moderate Buy
Current: 30.680
Low
15.00
Averages
43.50
High
60.00
Current: 30.680
Low
15.00
Averages
43.50
High
60.00
BofA
Alec Stranahan
Underperform
maintain
$13 -> $15
2026-01-06
Reason
BofA
Alec Stranahan
Price Target
$13 -> $15
AI Analysis
2026-01-06
maintain
Underperform
Reason
BofA analyst Alec Stranahan raised the firm's price target on TG Therapeutics to $15 from $13 and keeps an Underperform rating on the shares. The firm is updating its price targets for U.S Biopharmaceuticals under its coverage, the analyst tells investors. Over the past few months, several key items "have fallen into place," including positive data catalysts being rewarded; large-cap biopharma spending cash on M&A and in-licensing; growing backlog of companies on the private side; improving access to capital; and limited impact from drug price regulation, BofA says. The firm believes biotech is back, but the biggest concern is whether this will last.
JPMorgan
Eric Joseph
Overweight
maintain
$46 -> $49
2025-11-03
Reason
JPMorgan
Eric Joseph
Price Target
$46 -> $49
2025-11-03
maintain
Overweight
Reason
JPMorgan analyst Eric Joseph raised the firm's price target on TG Therapeutics to $49 from $46 and keeps an Overweight rating on the shares. The firm updated the company's model post earnings.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for TGTX
Unlock Now
B. Riley
B. Riley
maintain
$53 -> $55
2025-09-17
Reason
B. Riley
B. Riley
Price Target
$53 -> $55
2025-09-17
maintain
Reason
B. Riley raised the firm's price target on TG Therapeutics to $55 from $53 and keeps a Buy rating on the shares. The firm believes the company is positioned for multi-year Briumvi U.S. sales growth. It sees the drug being on track to exceed $1B in the next few years. Riley recommends using the post-earnings selloff in shares of TG as a buying opportunity.
Goldman Sachs
Corinne Johnson
Neutral
initiated
$37
2025-07-10
Reason
Goldman Sachs
Corinne Johnson
Price Target
$37
2025-07-10
initiated
Neutral
Reason
Goldman Sachs analyst Corinne Johnson initiated coverage of TG Therapeutics with a Neutral rating and $37 price target. The firm believes Briuvmi revenue growth will continue to be the key driver of the shares.
About TGTX
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates are Ublituximab IV (anti-CD20 mAb), Ublituximab Subcutaneous (anti-CD20 mAb), Azer-cel, TG-1701 (BTK inhibitor), and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition, and/or investment opportunities.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
